Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia 1
dc.contributor.author | Groeneveld, Peter W. | en_US |
dc.contributor.author | Lieu, Tracy A. | en_US |
dc.contributor.author | Fendrick, A. Mark | en_US |
dc.contributor.author | Hurley, Leo B. | en_US |
dc.contributor.author | Ackerson, Lynn M. | en_US |
dc.contributor.author | Levin, Theodore R. | en_US |
dc.contributor.author | Allison, James E. | en_US |
dc.date.accessioned | 2010-06-01T19:54:05Z | |
dc.date.available | 2010-06-01T19:54:05Z | |
dc.date.issued | 2001-02 | en_US |
dc.identifier.citation | Groeneveld, Peter W . ; Lieu, Tracy A . ; Fendrick, A. Mark; Hurley, Leo B . ; Ackerson, Lynn M . ; Levin, Theodore R . ; Allison, James E . (2001). "Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia 1 ." The American Journal of Gastroenterology 96(2): 338-347. <http://hdl.handle.net/2027.42/73031> | en_US |
dc.identifier.issn | 0002-9270 | en_US |
dc.identifier.issn | 1572-0241 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/73031 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11232673&dopt=citation | en_US |
dc.description.abstract | Previous economic studies of Helicobacter pylori eradication in dyspepsia and peptic ulcer disease have not measured quality of life using utilities (preference probabilities), which are needed to compare the cost-effectiveness of such treatment to other health care interventions. The goals of this study were to measure quality of life in patients with dyspepsia or peptic ulcer and apply these measurements to published models of disease management to determine cost-effectiveness in dollars per quality-adjusted life year (QALY) gained. Methods : Utilities for dyspepsia and peptic ulcer disease were measured in adult patients (n = 73) on chronic acid suppression for peptic ulcer or ulcer-like dyspepsia. Median utility values were applied to the results of published cost-effectiveness analyses and a previously validated dyspepsia model. Cost-utility ratios for early H. pylori eradication in uninvestigated dyspepsia and peptic ulcer disease were then computed. Results : The total disutility, or lost quality of life, for an ulcer was 0.11 QALY, of which 0.09 QALY was attributed to dyspeptic symptoms. After these results were incorporated into published studies, cost-utility ratios for ulcer treatment varied from $3,100 to $12,500 per QALY gained, whereas estimates for uninvestigated dyspepsia management ranged from $26,800 to $59,400 per QALY. Sensitivity analyses indicated a range of $1,300 to $27,300 per QALY for management of duodenal ulcer and $15,000 to $129,700 per QALY for dyspepsia. Conclusions: Strategies that emphasize early H. pylori eradication were cost-effective for patients with peptic ulcer and possibly cost-effective for patients with uninvestigated dyspepsia, relative to other medical interventions. Dyspeptic symptoms cause significant disutility that should be incorporated in future cost-effectiveness analyses of treatment strategies. | en_US |
dc.format.extent | 80075 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | 2001 by Am. Coll. of Gastroenterology | en_US |
dc.title | Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia 1 | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of General Medicine, University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | Department of Veterans Affairs Medical Center and University of California, San Francisco, San Francisco, California, USA | en_US |
dc.contributor.affiliationother | Center for Health Policy, Stanford University, Stanford, California, USA | en_US |
dc.contributor.affiliationother | Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School, Boston, Massachusetts, USA | en_US |
dc.contributor.affiliationother | Division of Research, Kaiser Permanente Medical Care Program (Northern California Region), Oakland, California, USA | en_US |
dc.contributor.affiliationother | Department of Gastroenterology, Kaiser Permanente Medical Center, Walnut Creek, California, USA | en_US |
dc.contributor.affiliationother | Division of Gastroenterology, San Francisco General Hospital, San Francisco, California, USA | en_US |
dc.contributor.affiliationother | Northern California Institute for Research and Education, San Francisco, California, USA | en_US |
dc.identifier.pmid | 11232673 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/73031/1/j.1572-0241.2001.03516.x.pdf | |
dc.identifier.doi | 10.1111/j.1572-0241.2001.03516.x | en_US |
dc.identifier.source | The American Journal of Gastroenterology | en_US |
dc.identifier.citedreference | Craig A.M., Davey P., Malek M., et al. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. Pharmacoeconomics 1996; 10: 79 – 92. | en_US |
dc.identifier.citedreference | Briggs A.H., Sculpher M.J., Logan R.P., et al. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. Br Med J 1996; 312: 1321 – 1325. | en_US |
dc.identifier.citedreference | Cromwell D.M., Pasricha P.J. Endoscopy or empirical treatment for peptic ulcer disease: Decisions, decisions. Gastroenterology 1996; 110: 1314 – 1316. | en_US |
dc.identifier.citedreference | Deltenre M., Ilunga K.O. Helicobacter pylori eradication in duodenal ulcer disease is cost-beneficial: A Belgian model. J Physiol Pharmacol 1997; 48 ( suppl 4 ): 107 – 113. | en_US |
dc.identifier.citedreference | Duggan A.E., Tolley K., Hawkey C.J., et al. Varying efficacy of Helicobacter pylori eradication regimens: Cost effectiveness study using a decision analysis model. Br Med J 1998; 316: 1648 – 1654. | en_US |
dc.identifier.citedreference | Ebell M.H., Warbasse L., Brenner C. Evaluation of the dyspeptic patient: A cost-utility study. J Fam Pract 1997; 44: 545 – 555. | en_US |
dc.identifier.citedreference | Fendrick A.M., Chernew M.E., Hirth R.A., et al. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med 1995; 123: 260 – 268. | en_US |
dc.identifier.citedreference | Fendrick A.M., McCort J.T., Chernew M.E., et al. Immediate eradication of Helicobacter pylori in patients with previously documented peptic ulcer disease: Clinical and economic effects. Am J Gastroenterol 1997; 92: 2017 – 2024. | en_US |
dc.identifier.citedreference | Habu Y., Inokuchi H., Kiyota K., et al. Economic evaluation of Helicobacter pylori eradication for the treatment of duodenal ulcer disease in Japan: A decision analysis to assess eradication strategy in comparison with a conventional strategy. J Gastroenterol Hepatol 1998; 13: 280 – 287. | en_US |
dc.identifier.citedreference | Imperiale T.F., Speroff T., Cebul R.D., et al. A cost analysis of alternative treatments for duodenal ulcer. Ann Intern Med 1995; 123: 665 – 672. | en_US |
dc.identifier.citedreference | Jonsson B. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease. Scand J Gastroenterol 1996; 215 ( suppl ): 90 – 95. | en_US |
dc.identifier.citedreference | Levin T.R., Schmittdiel J.A., Henning J.M., et al. A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization. Am J Gastroenterol 1998; 93: 743 – 747. | en_US |
dc.identifier.citedreference | O'Brien B., Goeree R., Mohamed A.H., et al. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995; 155: 1958 – 1964. | en_US |
dc.identifier.citedreference | Ofman J.J., Etchason J., Fullerton S., et al. Management strategies for Helicobacter pylori -seropositive patients with dyspepsia: Clinical and economic consequences. Ann Intern Med 1997; 126: 280 – 291. | en_US |
dc.identifier.citedreference | Phull P.S., Ryder S.D., Halliday D., et al. The economic and quality-of-life benefits of Helicobacter pylori eradication in chronic duodenal ulcer disease—A community-based study. Postgrad Med J 1995; 71: 413 – 418. | en_US |
dc.identifier.citedreference | Powell K.U., Bell G.D., Bolton G.H., et al. Helicobacter pylori eradication in patients with peptic ulcer disease: Clinical consequences and financial implications. Q J Med 1994; 87: 283 – 290. | en_US |
dc.identifier.citedreference | Silverstein M.D., Petterson T., Talley N.J. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: A decision analysis. Gastroenterology 1996; 110: 72 – 83. | en_US |
dc.identifier.citedreference | Sonnenberg A., Townsend W.F. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med 1995; 155: 922 – 928. | en_US |
dc.identifier.citedreference | Sonnenberg A. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects. Am J Gastroenterol 1996; 91: 1773 – 1777. | en_US |
dc.identifier.citedreference | Sonnenberg A., Schwartz J.S., Cutler A.F., et al. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: Results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. Arch Intern Med 1998; 158: 852 – 860. | en_US |
dc.identifier.citedreference | Unge P., Jonsson B., Stalhammar N.O. The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden. Pharmacoeconomics 1995; 8: 410 – 427. | en_US |
dc.identifier.citedreference | Vakil N., Fennerty M.B. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. Am J Gastroenterol 1996; 91: 239 – 245. | en_US |
dc.identifier.citedreference | Vakil N, Fennerty B. The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease. Am J Med 1996; 100: 60 – 4S. | en_US |
dc.identifier.citedreference | Weinstein M.C., Siegel J.E., Gold M.R., et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253 – 1258. | en_US |
dc.identifier.citedreference | Siegel J.E., Weinstein M.C., Russell L.B., et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1339 – 1341. | en_US |
dc.identifier.citedreference | Russell L.B., Gold M.R., Siegel J.E., et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1172 – 1177. | en_US |
dc.identifier.citedreference | Torrance G.W. Social preferences for health states: An empirical evaluation of three measurement techniques. Socioecon Plann Sci 1976; 10: 129 – 136. | en_US |
dc.identifier.citedreference | Clarke A.E., Goldstein M.K., Michelson D., et al. The effect of assessment method and respondent population on utilities elicited for Gaucher disease. Qual Life Res 1997; 6: 169 – 184. | en_US |
dc.identifier.citedreference | Johannesson M. Theory, and methods of economic evaluation of health care. Boston: Kluwer, 1996. | en_US |
dc.identifier.citedreference | Sonnenberg A., Everhart J.E. Health impact of peptic ulcer in the United States. Am J Gastroenterol 1997; 92: 614 – 620. | en_US |
dc.identifier.citedreference | 31. Health, United States, 1998. Hyattsville, MD: Centers for Disease Control and Prevention, National Center for Health Statistics, 1999. | en_US |
dc.identifier.citedreference | Jibril J.A., Redpath A., MacIntyre I.M.C. Changing pattern of admission and operation for duodenal ulcer in Scotland. Br J Surg 1994; 81: 87 – 89. | en_US |
dc.identifier.citedreference | Petersen H., Kristensen P., Johannessen T., et al. The natural course of peptic ulcer disease and its predictors. Scand J Gastroenterol 1995; 30: 17 – 24. | en_US |
dc.identifier.citedreference | Heaney A., Collins J.S., Watson R.G., et al. A prospective randomised trial of a “test and treat” policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999; 45: 186 – 190. | en_US |
dc.identifier.citedreference | Talley N.J., Janssens J., Lauritsen K., et al. Eradication of Helicobacter pylori in functional dyspepsia: Randomised double blind placebo controlled trial with 12 months’ follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. Br Med J 1999; 318: 833 – 837. | en_US |
dc.identifier.citedreference | McColl K., Murray L., El-Omar E., et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998; 339: 1869 – 1874. | en_US |
dc.identifier.citedreference | Blum A.L., Talley N.J., O'Morain C., et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998; 339: 1875 – 1881. | en_US |
dc.identifier.citedreference | Archimandritis A., Balatsos V., Delis V., et al. “ Reappearance” of Helicobacter pylori after eradication: Implications on duodenal ulcer recurrence: A prospective 6 year study. J Clin Gastroenterol 1999; 28: 345 – 347. | en_US |
dc.identifier.citedreference | Ciociola A.A., McSorley D.J., Turner K., et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999; 94: 1834 – 1840. | en_US |
dc.identifier.citedreference | Gisbert J.P., Pajares J.M., Garcia-Valriberas R., et al. Recurrence of Helicobacter pylori infection after eradication. Incidence and variables influencing it. Scand J Gastroenterol 1998; 33: 1144 – 1151. | en_US |
dc.identifier.citedreference | Stone M.A., Barnett D.B., Mayberry J.F. Lack of correlation between self-reported symptoms of dyspepsia and infection with Helicobacter pylori, in a general population sample. Eur J Gastroenterol Hepatol 1998; 10: 301 – 304. | en_US |
dc.identifier.citedreference | Boutet R. Management of dyspepsia in primary care. GPs are already choosing eradication therapy over endoscopy. Br Med J 1998; 316: 1388 ( letter ) | en_US |
dc.identifier.citedreference | Howden C.W., Hunt R.H. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2330 – 2338. | en_US |
dc.identifier.citedreference | Moayyedi P. What is the optimum strategy for managing dyspepsia?. J Gastroenterol 1998; 33 ( suppl 10 ): 44 – 47. | en_US |
dc.identifier.citedreference | Parry J.M., Foy R.C., Woodman C.B. How might general practitioner knowledge of patient Helicobacter pylori status change the management of dyspepsia in primary care?. J Public Health Med 1998; 20: 133 – 136. | en_US |
dc.identifier.citedreference | 46. US Census Bureau. Census, California Congressional District Data. Available from the U.S. Census Bureau via the Internet ( http://www.census.gov ). Accessed 29 Jul 1999. | en_US |
dc.identifier.citedreference | Laupacis A., Feeny D., Detsky A.S., et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473 – 481. | en_US |
dc.identifier.citedreference | Revicki D.A., Wood M., Wiklund I., et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998; 7: 75 – 83. | en_US |
dc.identifier.citedreference | Revicki D.A., Wood M., Maton P.N., et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 252 – 258. | en_US |
dc.identifier.citedreference | Velanovich V., Vallance S.R., Gusz J.R., et al. Quality of life scale for gastroesophageal reflux disease. J Am Coll Surg 1996; 183: 217 – 224. | en_US |
dc.identifier.citedreference | Blumenschein K., Johannesson M. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Ann Allergy Asthma Immunol 1998; 80: 189 – 194. | en_US |
dc.identifier.citedreference | Bult J.R., Hunink M.G., Tsevat J., et al. Heterogeneity in the relationship between the time tradeoff and Short Form-36 for HIV-infected and primary care patients. Med Care 1998; 36: 523 – 532. | en_US |
dc.identifier.citedreference | Chancellor J.V., Coyle D., Drummond M.F. Constructing health state preference values from descriptive quality of life outcomes: Mission impossible?. Qual Life Res 1997; 6: 159 – 168. | en_US |
dc.identifier.citedreference | Fryback D.G., Lawrence W.F., Martin P.A., et al. Predicting quality of well-being scores from the SF-36: Results from the Beaver Dam Health Outcomes Study. Med Decis Making 1997; 17: 1 – 9. | en_US |
dc.identifier.citedreference | Graham D.Y., Lew G.M., Klein P.D., et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992; 116: 705 – 708. | en_US |
dc.identifier.citedreference | Hentschel E., Brandstatter G., Dragosics B., et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308 – 312. | en_US |
dc.identifier.citedreference | Talley N.J., Vakil N., Ballard E.D., II, et al. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999; 341: 1106 – 1111. | en_US |
dc.identifier.citedreference | McColl K., Murray L., El-Omar E., et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998; 339: 1869 – 1874. | en_US |
dc.identifier.citedreference | Danesh J., Lawrence M., Murphy M., et al. Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia. Arch Intern Med 2000; 160: 1192 – 1198. | en_US |
dc.identifier.citedreference | Gold M.R., Siegel J.E., Russell L.B., et al. eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 82 – 134 | en_US |
dc.identifier.citedreference | 61. OANDA Currency converter. Olson, and Associates. Available via the Internet ( http://www.oanda.com ). Accessed 15 Jul 1999. | en_US |
dc.identifier.citedreference | Hamel M.B., Phillips R.S., Davis R.B., et al. Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med 1997; 127: 195 – 202. | en_US |
dc.identifier.citedreference | Provenzale D., Schmitt C., Wong J.B. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94: 2043 – 2053. | en_US |
dc.identifier.citedreference | Lee S.J., Anasetti C., Kuntz K.M., et al. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood 1998; 92: 4047 – 4052. | en_US |
dc.identifier.citedreference | Gerson L.B., Robbins A.S., Garber A., et al. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 395 – 407. | en_US |
dc.identifier.citedreference | Lieu T.A., Gurley R.J., Lundstrom R.J., et al. Projected cost-effectiveness of primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1741 – 1750. | en_US |
dc.identifier.citedreference | Chang R.W., Pellisier J.M., Hazen G.B. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA 1996; 275: 858 – 865. | en_US |
dc.identifier.citedreference | Younossi Z.M., Singer M.E., McHutchison J.G., et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 1318 – 1324. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.